Steady Quiet Asthma Without Biologics: One-Year Outcomes of Single-Inhaler Triple Therapy for Severe Asthma with Small Airway Dysfunction.

Small airway dysfunction (SAD) plays a critical role in the management of severe asthma, particularly in patients at risk of requiring biological therapies (BTs). Short-term studies have shown that switching to single-inhaler triple therapy (SITT) with extrafine beclomethasone-formoterol-glycopyrronium improves outcomes and helps achieve quiet asthma, a state marked by symptom control, no exacerbations or oral steroids, reduced inflammation, and better small airway function. This study investigated whether, over one year, patients could maintain this state as Steady Quiet Asthma (SQA) and whether baseline measures could predict this sustained response.

Real-life preliminary evidence for basophils as predictors of Tezepelumab response in severe asthma.

Background: Severe asthma is a complex disease with persistent symptoms despite high-dose inhaled therapy. Tezepelumab, a monoclonal antibody targeting thymic stromal lymphopoietin (TSLP), has shown efficacy across asthma phenotypes. However, identifying early responders remains a challenge.

Diaphragm function in patients with asthma and healthy controls: A cross-sectional study.

Background: Asthma is a chronic respiratory disease characterized by airway inflammation and variable respiratory symptoms. While peripheral muscle deconditioning is known to affect lung function and exercise tolerance, the role of respiratory muscle dysfunction, particularly the diaphragm, remains underexplored.

Objective: We aim to evaluate potential differences in diaphragm function in patients with asthma.